Drug Profile
Research programme: G-protein coupled receptor agonists - Confo Therapeutics/Roche
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Confo Therapeutics
- Developer Confo Therapeutics; Roche
- Class Neuroprotectants; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Developmental disabilities; Neurological disorders
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Developmental-disabilities in Belgium
- 28 Jan 2022 No recent reports of development identified for research development in Neurological-disorders in Belgium
- 15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union